info@tiba.bio
 

ABOUT USOur History

Based on a multi-institute, multi-lab sponsored research program, we are advancing novel vaccines and therapeutics for human health

2015

SEPTEMBER 2015

Provisional Patent Application

M.I.T. and the Whitehead Institute file the initial provisional patent application to a novel class of dendrimer nanoparticles: Compositions and Methods for Modified Dendrimer Nanoparticle Delivery.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2016

AUGUST 2016

Seminal Publication

Chahal JS, Khan OF, Cooper CL, McPartlan JS, Tsosie JK, Tilley LD, Sidik SM, Lourido S, Langer R, Bavari S, Ploegh HL, Anderson DG. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):E4133-42. 

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2017

MARCH 2017

Rapid Seven Day Development of Zika Virus Vaccine for US Military

M.I.T. and Whitehead colleagues delivered a protective Zika Virus vaccine candidate to our collaborators at the United States Army Medical Research Institute of Infectious Diseases. Chahal JS, Fang T, Woodham AW, Khan OF, Ling J, Anderson DG, Ploegh HL. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci Rep. 2017 Mar 21;7(1):252. 

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2018

MARCH 2018

Tiba Biotech emerges from the university lab

Tiba raises its first round of seed capital, secures a research grant from the Bill and Melinda Gates Foundation’s Livestock Vaccine Innovation Fund, and establishes a collaboration with colleagues at the United States Army Medical Research Institute of Infectious Diseases focused (USAMRIID).

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2019

MARCH 2019

Closing of Initial Seed Funding

In parallel with completing a funded benchmarking study for the Bill and Melinda Gates Foundation, Tiba completes an over-subscribed round of +$2M in funding from a group of individuals and  international investors interested in supporting global health and rapid response vaccines.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2020

FEBRUARY 2020

Patent Issued and Grants Awarded

The United States Patent and Trademark Office issues Patent No. 10,548,959, Compositions and Methods for Modified Dendrimer Nanoparticle Delivery, followed by a grant with the University of Pittsburg’s Center for Vaccine Research to advance a microarray vaccine patch and a collaboration with the King Abdullah University of Science and Technology to develop a novel prime-boost vaccine prototype.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2021

August 2021

CIVICs Universal Influenza and COVID-19 Collaborations

The NIH Collaborative Influenza Vaccine Innovation Centers (CIVICs) initiative invites Tiba to join the effort to develop a novel universal influenza vaccine candidate, in collaboration with Prof. Florian Krammer of the Icahn School of Medicine at Mount Sinai.  This is on the heels of a $2.5M international consortium led by Tiba to pursue a heterologous prime-boost vaccine broadly protective against a range of betacoronaviruses, including mutant strains of SARS-CoV-2.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2022

February 2022

New NIH Funding of Pandemic Avian Influenza Vaccines

What is to become a leading vaccine candidate in our pipeline, the NIH awards Tiba a Phase I SBIR grant to develop a vaccine against the highly pathogenic H7N9 strain of influenza virus.  An additional NIH grant soon follows, focused on tick bourn diseases.

December 2022

Tiba demonstrates nasal delivery of RNABL nanoparticles in mice

Collaborators from the NIH Collaborative Influenza Vaccine Innovation Centers (CIVICs) consortium showed that nasal delivery of an RNABL vaccine induced adaptive immune responses in the respiratory tracts of mice. See Künzli et al., Sci Immunol. Vol. 7 No. 78 (Dec 2022). Künzli et al., Sci Immunol. Vol. 7 No. 78 (Dec 2022).

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2023

January 2023

CEPI and Tiba undertake a benchmarking study of the RNABL™ Vaccine Platform

CEPI partners with Tiba Biotech to evaluate the next-generation RNA vaccine platform technology. As part of the $3.5 billion ‘DiseaseX’ initiative, CEPI has committed US$2 million to advance Tiba Biotech’s novel RNA nanoparticle delivery platform, RNABL™, with a candidate vaccine against the Japanese Encephalitis Virus (JEV) .

September 2023

Additional funding from the NIH to advance a multi-antigen pandemic avian influenza vaccine

Tiba Biotech secures an NIH Phase II SBIR grant to continue its development of a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.  This three year, $3 million funding will leverage an earlier program, toward a pre-IND filing with the FDA.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2024

MAY 2024

Tiba Manufactures a Next-Generation Livestock Vaccine in Australia

The government of NSW (Australia) is investing in a range of animal disease vaccines with leading institutions and technology providers, including Tiba Biotech. A pilot project intended to fast-track an mRNA vaccine for border disease virus (BDV) has been successfully manufactured for the first time in NSW.

July 2024

BARDA Funds Tiba to Develop a Novel Therapeutic

Tiba secures a FASTx award from the Biomedical Advanced Research and Development Authority (BARDA) to develop an RNAi-based therapeutic for H1N1 influenza, extending Tiba’s RNABL™ delivery platform beyond vaccines. Tiba was also accepted to the Blue Knight program, a joint initiative between BARDA and Johnson & Johnson Innovations – JLABS.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

ORIGINSRooted in Science with a Vision Toward Global Health

From over five years of university sponsored research in pandemic preparedness, Tiba is today focusing on vaccines and tomorrow expanding to therapeutics.

Vaccines

Rapid response to infectious diseases

Therapeutics

Oncology to gene editing applications

Tiba’s founding team of entrepreneurial scientists come from across academia and industry, advancing core innovations developed at the Massachusetts Institute of Technology and the Whitehead Institute.  With our early focus on vaccines, Tiba is expanding toward a range of therapeutic applications with our strategic partners.

https://i0.wp.com/tiba.bio/wp-content/uploads/2020/06/large_blue_triangle_04.png?fit=484%2C481&ssl=1

VISIONWhat's in a Name?

An international team dedicated to impacting the world around us.

Advancing science

Continuous innovation in RNA delivery

One World

Improved human health beyond boarders

Tiba, n.        (plural: tiba)
/tiː ˈ ba/

Etymology: Swahili, from Arabic  طِبّ‎  (ṭibb, “medicine”)

1. medical treatment or therapy

  • medical care given to a patient for an illness or injury.
  • a session of medical care or the administration of a dose of medicine.

2. cure

  • a substance or treatment that cures a disease or medical condition.
https://i0.wp.com/tiba.bio/wp-content/uploads/2020/06/large_blue_triangle_01.png?fit=474%2C468&ssl=1

PANDEMIC PREPAREDNESSRapid Response

An early-stage team building the foundation to address future pandemic risks.

SARS-CoV 2

New addition to a long history of pandemic targets

Vaccines

Multi-antigen approach to a rapidly emerging virus

Tiba is accelerating the development of an RNA delivery platform, RNABL, in the face of emerging pandemic threats.  Leveraging a range of US and international grants, the dedicated team has ongoing collaborations with leading researches and institutions.

https://i0.wp.com/tiba.bio/wp-content/uploads/2021/05/Tiba-small-logo2.png?fit=140%2C58&ssl=1
info@tiba.bio
1 Broadway, 14th Fl., Cambridge MA

Keep connected with us

Check out our careers page
See what we are doing!

© 2024 Tiba Biotech LLC. All rights reserved

Terms and Conditions